Rethinking Alzheimer's: Mapping Out an Approval Process
This article was originally published in RPM Report
Executive Summary
Drug companies involved in Alzheimer's disease research are a little fed up with FDA. Some, like Wyeth, believe the agency should put Alzheimer's research higher up on its priority list and allow the use of surrogate endpoints for clinical trials. But FDA says that no validated surrogate exists for Alzheimer's, and until it has hard data from products in development, it is loath to recommend one. A recent reorganization of the agency's neurology group may provide an opening to press home those arguments.
You may also be interested in...
FDA Responds to Nagging Questions About “Lagging” Drug Review Divisions
It’s a question FDA has heard on Capitol Hill throughout the 21st Century Cures process: Why can’t all drug review divisions keep pace with the approvals seen in the oncology office – and shouldn’t steps be taken to ease development pathways for “lagging” conditions like Alzheimer’s and rare diseases? In the face of a tougher “Cures” debate in the Senate, FDA issues a white paper to more fully outline its response.
A New Direction For Alzheimer’s R&D: FDA Outlines Early Disease Pathway
Alzheimer’s R&D has suffered multiple failures over the last decade, with no drug found to slow or halt the underlying progression of the disease. Industry’s focus is now on patients at the very earliest stages of the disease, and FDA is meeting sponsors halfway, with a draft guidance outlining approval requirements.
A New Direction for Alzheimer’s R&D: FDA Outlines Early Disease Pathway
Alzheimer’s R&D has suffered multiple failures over the last decade, with no drug found to slow or halt the underlying progression of the disease. Industry’s focus is now on patients at the very earliest stages of Alzheimer’s in the hopes of finding an effective drug before too much damage is done. FDA is meeting sponsors halfway, with a draft guidance outlining approval requirements.